Literature DB >> 11767010

The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

S P Saini1, A K Srivastava.   

Abstract

The disposition kinetics, urinary excretion and a dosage regimen for ciprofloxacin after a single intravenous administration of 5 mg/kg was investigated in 5 healthy buffalo calves. The disposition kinetics were best fitted to a three-compartment open model. After 1 min, the concentration of ciprofloxacin in plasma was 8.50 +/- 0.39 microg/ml and the minimum therapeutic concentration was maintained for 10 h. The elimination half-life and volume of distribution were 3.88 and 0.08 h and 3.97 +/- 0.22 L/kg, respectively. The total body clearance and T/P ratio were 0.709 +/- 0.025 L/kg per h and 6.13 +/- 0.54, respectively. Approximately 28.3% of the total administered dose of ciprofloxacin was recovered in urine within 24 h of administration. To maintain a minimum therapeutic plasma concentration of 0.10 microg/ml, a satisfactory intravenous dosage regimen of ciprofloxacin, computed on the basis of disposition kinetic data obtained in healthy buffalo calves, would be 3 mg/kg repeated at 12 h intervals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11767010     DOI: 10.1023/a:1012791113342

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  18 in total

1.  A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog.

Authors:  C C Cester; P L Toutain
Journal:  J Pharm Sci       Date:  1997-10       Impact factor: 3.534

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Outline of details for microbiological assays of antibiotics: second revision.

Authors:  B Arret; D P Johnson; A Kirshbaum
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

4.  The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin).

Authors:  K Alestig
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  Pharmacokinetics of ciprofloxacin in ponies.

Authors:  P M Dowling; R C Wilson; J W Tyler; S H Duran
Journal:  J Vet Pharmacol Ther       Date:  1995-02       Impact factor: 1.786

Review 6.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  The pharmacokinetics and tissue penetration of the fluoroquinolones.

Authors:  M G Bergeron
Journal:  Clin Invest Med       Date:  1989-02       Impact factor: 0.825

8.  Disposition of ciprofloxacin following intravenous administration in dogs.

Authors:  A R Abadía; J J Aramayona; M J Muñoz; J M Pla Delfina; M P Saez; M A Bregante
Journal:  J Vet Pharmacol Ther       Date:  1994-10       Impact factor: 1.786

Review 9.  Ciprofloxacin: in vitro activity, mechanism of action, and resistance.

Authors:  C C Sanders
Journal:  Rev Infect Dis       Date:  1988 May-Jun

10.  Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.

Authors:  R A Blum
Journal:  Am J Med       Date:  1992-04-06       Impact factor: 4.965

View more
  3 in total

1.  Transformation of the antibacterial agent norfloxacin by environmental mycobacteria.

Authors:  Michael D Adjei; Thomas M Heinze; Joanna Deck; James P Freeman; Anna J Williams; John B Sutherland
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

2.  Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.

Authors:  Eva Hong; Sara Thulin Hedberg; Raquel Abad; Cecilia Fazio; Rocío Enríquez; Ala-Eddine Deghmane; Keith A Jolley; Paola Stefanelli; Magnus Unemo; Julio A Vazquez; Frédéric J Veyrier; Muhamed-Kheir Taha
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

3.  Pharmacokinetic-pharmacodynamic integration of enrofloxacin and its metabolite ciprofloxacin in buffalo calves.

Authors:  Prashant S Daundkar; Bhaskar Vemu; Vinod K Dumka; Suresh K Sharma
Journal:  Vet Med Sci       Date:  2015-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.